127 related articles for article (PubMed ID: 15385119)
1. A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
Clamp A; Adams M; Atkinson R; Boven E; Calvert AH; Cervantes A; Ganesan T; Lotz J; Vasey P; Cheverton P; Jayson GC
Gynecol Oncol; 2004 Oct; 95(1):114-9. PubMed ID: 15385119
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
[TBL] [Abstract][Full Text] [Related]
3. A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.
Esteva FJ; Rivera E; Cristofanilli M; Valero V; Royce M; Duggal A; Colucci P; DeJager R; Hortobagyi GN
Cancer; 2003 Sep; 98(5):900-7. PubMed ID: 12942555
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
Sharma S; Kemeny N; Schwartz GK; Kelsen D; O'Reilly E; Ilson D; Coyle J; De Jager RL; Ducharme MP; Kleban S; Hollywood E; Saltz LB
Clin Cancer Res; 2001 Dec; 7(12):3963-70. PubMed ID: 11751488
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
Lee HP; Seo SS; Ryu SY; Kim JH; Bang YJ; Park SY; Nam JH; Kang SB; Lee KH; Song YS
Gynecol Oncol; 2008 Jun; 109(3):359-63. PubMed ID: 18405948
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Braybrooke JP; Boven E; Bates NP; Ruijter R; Dobbs N; Cheverton PD; Pinedo HM; Talbot DC
Ann Oncol; 2003 Jun; 14(6):913-21. PubMed ID: 12796030
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.
Matsumoto K; Katsumata N; Yamanaka Y; Yonemori K; Kohno T; Shimizu C; Andoh M; Fujiwara Y
Gynecol Oncol; 2006 Feb; 100(2):412-6. PubMed ID: 16298422
[TBL] [Abstract][Full Text] [Related]
8. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Giles FJ; Cortes JE; Thomas DA; Garcia-Manero G; Faderl S; Jeha S; De Jager RL; Kantarjian HM
Clin Cancer Res; 2002 Jul; 8(7):2134-41. PubMed ID: 12114413
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
[TBL] [Abstract][Full Text] [Related]
12. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Reichardt P; Nielsen OS; Bauer S; Hartmann JT; Schöffski P; Christensen TB; Pink D; Daugaard S; Marreaud S; Van Glabbeke M; Blay JY;
Eur J Cancer; 2007 Apr; 43(6):1017-22. PubMed ID: 17336054
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.
Verschraegen CF; Levenback C; Vincent M; Wolf J; Bevers M; Loyer E; Kudelka AP; Kavanagh JJ
Ann N Y Acad Sci; 2000; 922():349-51. PubMed ID: 11193920
[No Abstract] [Full Text] [Related]
14. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Boige V; Raymond E; Armand JP
Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
[TBL] [Abstract][Full Text] [Related]
15. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
Nishio S; Sugiyama T; Shouji T; Yoshizaki A; Kitagawa R; Ushijima K; Kamura T
Gynecol Oncol; 2007 Aug; 106(2):342-7. PubMed ID: 17499346
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).
Matsumoto K; Katsumata N; Shibata T; Satoh T; Saitou M; Yunokawa M; Takano T; Nakamura K; Kamura T; Konishi I
Gynecol Oncol; 2015 Feb; 136(2):218-23. PubMed ID: 25449313
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Dark GG; Calvert AH; Grimshaw R; Poole C; Swenerton K; Kaye S; Coleman R; Jayson G; Le T; Ellard S; Trudeau M; Vasey P; Hamilton M; Cameron T; Barrett E; Walsh W; McIntosh L; Eisenhauer EA
J Clin Oncol; 2005 Mar; 23(9):1859-66. PubMed ID: 15699482
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2004 Oct; 95(1):109-13. PubMed ID: 15385118
[TBL] [Abstract][Full Text] [Related]
19. Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: a Phase II study.
Salah-Eldin MA; Wahba HA; Halim AA
Indian J Cancer; 2012; 49(1):169-75. PubMed ID: 22842184
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.
Braybrooke JP; Ranson M; Manegold C; Mattson K; Thatcher N; Cheverton P; Sekiguchi M; Suzuki M; Oyama R; Talbot DC
Lung Cancer; 2003 Aug; 41(2):215-9. PubMed ID: 12871785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
